Takeda Pharma Gets US FDA Approval for Rare Blood Disorder Therapy
9:29 JST, November 10, 2023
Nov 9 (Reuters) – The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical’s 4502.T therapy to treat a rare genetic blood disorder in adult and pediatric patients.
Takeda’s Adzynma becomes the first treatment available to patients with congenital thrombotic thrombocytopenic purpura (TTP).
Congenital TTP is a life-threatening, rare genetic disorder with debilitating chronic symptoms. It leads to abnormal clotting in the small blood vessels throughout the body and is associated with anemia and low platelet levels.
The FDA said that most common side effects associated with the therapy include headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting.
The health regulator’s decision is based on the late-stage study of the drug, which showed it was able to reduce incidence of Thrombocytopenia, the most common symptom of the disease associated with low level of platelets, by 60% compared to standard of care.
Takeda expects Adzynma will be commercially available in December 2023, and pricing will be disclosed at that time, the president of its US business unit, Julie Kim, told Reuters.
The treatment, chemically known as TAK-755, helps in replacing the deficient protein ADAMTS13 that helps in blood clotting at the site of injury.
Currently plasma treatments, spleen surgeries and off-label use of Roche’s ROG.S blood cancer drug Rituxan are used to slow down or treat the condition.
"NEWS SERVICES" POPULAR ARTICLE
Japanese Actor-Director Kitano Says His New Film Explores Homosexual Relations in the Samurai World
Japan’s Nintendo Profits Jump as Its Game Sales Get a Boost from the Hit Super Mario Movie
Japan’s Nikkei Pares Early Gains as Investors Lock in Profits
Israel Searches for Traces of Hamas in Raid of Key Gaza Hospital Packed with Patients
Japan’s Nikkei Inches Down as Automakers Skid on Yen Strength
JN ACCESS RANKING
- Japan, Vietnam Trade Ministers Discuss Supply Chains, IPEF
- BOJ Ueda: Japan Increasingly Likely to Hit Inflation Target
- Stimulus Package Set to Drive Greater Govt Borrowing; Likely Effectiveness Called into Question
- Food, Beverage Price Hikes Show Signs of Easing; Fuel Prices, Consumer Frugality Slowing Down Price Rises
- Japan 2023 Food Exports Reach 1 Tril. Yen at Record Pace